Fundies.
English

Segment disclosures

Company overview

Endo International plc

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

60 dimension combinations 764 retained observations 22 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Adrenalin · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:AdrenalinMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3156512000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31179295000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3040311000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30133468000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3045835000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3093157000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3147322000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31143489000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3035460000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30101858000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Adrenalin · Sterile Injectables Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:AdrenalinMember;us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3199910000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3022873000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3075581000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3027133000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3052708000 USD20230808Open filing evidence
2022-01-01 – 2022-12-31114304000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3024917000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3085514000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3026774000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3060597000 USD20230808Open filing evidence
2022-01-01 – 2022-03-3133823000 USD20220506Open filing evidence
2021-01-01 – 2021-12-31901735000 RestatedUSD20240306Open filing evidence
2021-07-01 – 2021-09-3028722000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3088136000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3029977000 USD20210806Open filing evidence
2021-01-01 – 2021-06-3059414000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3129437000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31152074000 USD20230306Open filing evidence
2020-04-01 – 2020-06-3033161000 USD20210806Open filing evidence
2020-01-01 – 2020-06-3089673000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3156512000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31179295000 USD20210226Open filing evidence
2019-04-01 – 2019-06-3045835000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3093157000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31143489000 USD20210226Open filing evidence

Aplisol · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:AplisolMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-319867000 USD20200507Open filing evidence
2019-01-01 – 2019-12-3161826000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3028085000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3055996000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-03-3112381000 USD20200507Open filing evidence
2018-01-01 – 2018-12-3164913000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3015992000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-3049064000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Aplisol · Sterile Injectables Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:AplisolMember;us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-12-3136220000 USD20210226Open filing evidence
2020-07-01 – 2020-09-309443000 USD20201106Open filing evidence
2020-01-01 – 2020-09-3025821000 USD20201106Open filing evidence
2020-04-01 – 2020-06-306511000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3016378000 USD20200806Open filing evidence
2019-01-01 – 2019-12-3161826000 USD20210226Open filing evidence
2019-07-01 – 2019-09-3028085000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3055996000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3015530000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3027911000 USD20200806Open filing evidence
2018-01-01 – 2018-12-3164913000 USD20210226Open filing evidence

Ertapenem For Injection · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:ErtapenemForInjectionMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3117874000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31104679000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3021853000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3079619000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3025547000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3057766000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3132219000 USD20200507Open filing evidence
2018-01-01 – 2018-12-3157668000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3025798000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-3025798000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Ertapenem For Injection · Sterile Injectables Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:ErtapenemForInjectionMember;us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-12-3165607000 USD20210226Open filing evidence
2020-07-01 – 2020-09-3016784000 USD20201106Open filing evidence
2020-01-01 – 2020-09-3046648000 USD20201106Open filing evidence
2020-04-01 – 2020-06-3011990000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3029864000 USD20200806Open filing evidence
2019-01-01 – 2019-12-31104679000 USD20210226Open filing evidence
2019-07-01 – 2019-09-3021853000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3079619000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3025547000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3057766000 USD20200806Open filing evidence
2018-01-01 – 2018-12-3157668000 USD20210226Open filing evidence

Established Products · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:EstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31213427000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3052976000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30155392000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3047024000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30102416000 USD20230808Open filing evidence
2023-01-01 – 2023-03-3155392000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31229442000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3057171000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30168063000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3055089000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30110892000 USD20230808Open filing evidence
2022-01-01 – 2022-03-3155803000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31260467000 USD20240306Open filing evidence
2021-07-01 – 2021-09-3069060000 USD20211105Open filing evidence
2021-01-01 – 2021-09-30193314000 USD20211105Open filing evidence
2021-04-01 – 2021-06-3060949000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30124254000 USD20220809Open filing evidence
2021-01-01 – 2021-03-3163305000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31284702000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3083562000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30214115000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3060777000 USD20200806Open filing evidence
2020-01-01 – 2020-06-30130553000 USD20200806Open filing evidence
2020-01-01 – 2020-03-3169776000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31335726000 USD20220301Open filing evidence
2019-04-01 – 2019-06-3084920000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30173479000 USD20200806Open filing evidence

Established Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:EstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3169776000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31335726000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3085315000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30258794000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3084920000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30173479000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3188559000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31418257000 RestatedUSD20200226Open filing evidence
2018-07-01 – 2018-09-30107864000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30317943000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Lidoderm · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:LidodermMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3142464000 USD20240306Open filing evidence
2023-07-01 – 2023-09-309610000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3032199000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3011600000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3022589000 USD20230808Open filing evidence
2022-01-01 – 2022-12-3138727000 USD20240306Open filing evidence
2022-07-01 – 2022-09-309430000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3028331000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3010021000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3018901000 USD20230808Open filing evidence
2021-01-01 – 2021-12-3143636000 USD20240306Open filing evidence
2021-07-01 – 2021-09-3011686000 USD20211105Open filing evidence
2021-01-01 – 2021-09-3032314000 USD20211105Open filing evidence
2020-01-01 – 2020-12-3135234000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3018068000 USD20211105Open filing evidence
2020-01-01 – 2020-09-3026877000 USD20211105Open filing evidence
2019-01-01 – 2019-12-3155244000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3013236000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3040830000 USD20201106Open filing evidence
2018-01-01 – 2018-12-3158377000 USD20210226Open filing evidence

Opana · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OpanaMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-310 USD20190228Open filing evidence

Other Established Products · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OtherEstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3164588000 USD20240306Open filing evidence
2023-01-01 – 2023-03-3118347000 USD20230508Open filing evidence
2022-01-01 – 2022-12-3186772000 USD20240306Open filing evidence
2022-01-01 – 2022-03-3120748000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31113043000 USD20240306Open filing evidence
2021-01-01 – 2021-03-3126491000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31139356000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3037986000 USD20201106Open filing evidence
2020-01-01 – 2020-09-30104449000 USD20201106Open filing evidence
2020-04-01 – 2020-06-3019539000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3045821000 USD20200806Open filing evidence
2020-01-01 – 2020-03-3133881000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31164470000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3043518000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30129765000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3039329000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3083088000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31236979000 USD20210226Open filing evidence

Other Established Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OtherEstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3133505000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31164470000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3043518000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30129765000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3044262000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3086247000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3151828000 RestatedUSD20200507Open filing evidence
2018-01-01 – 2018-12-31236979000 RestatedUSD20200226Open filing evidence
2018-07-01 – 2018-09-3061172000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30179428000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Other Specialty Products · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OtherSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3173797000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3015749000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3057282000 USD20231106Open filing evidence
2023-01-01 – 2023-03-3121694000 USD20230508Open filing evidence
2022-01-01 – 2022-12-3170009000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3011033000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3050023000 USD20231106Open filing evidence
2022-01-01 – 2022-03-3120744000 USD20230508Open filing evidence
2021-01-01 – 2021-12-3186432000 USD20240306Open filing evidence
2021-07-01 – 2021-09-3026339000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3074407000 USD20221109Open filing evidence
2021-01-01 – 2021-03-3120032000 USD20210507Open filing evidence
2020-01-01 – 2020-12-3192662000 USD20210226Open filing evidence
2020-07-01 – 2020-09-3023724000 USD20211105Open filing evidence
2020-01-01 – 2020-09-3068795000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3019566000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3045071000 USD20200806Open filing evidence
2020-01-01 – 2020-03-3125505000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31105241000 USD20210226Open filing evidence
2019-07-01 – 2019-09-3028470000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3078397000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3025524000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3049927000 USD20200806Open filing evidence
2018-01-01 – 2018-12-3198230000 USD20210226Open filing evidence

Other Specialty Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OtherSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3125505000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31105241000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3028470000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3078397000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3025524000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3049927000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3124403000 USD20200507Open filing evidence
2018-01-01 – 2018-12-3198230000 RestatedUSD20200226Open filing evidence
2018-07-01 – 2018-09-3027614000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-3069226000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Other Sterile Injectables · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OtherSterileInjectablesMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3149233000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31185594000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3043695000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30124026000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3056872000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30108242000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3138989000 RestatedUSD20200507Open filing evidence
2018-01-01 – 2018-12-31209729000 RestatedUSD20200226Open filing evidence
2018-07-01 – 2018-09-3047567000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30161740000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Other Sterile Injectables · Sterile Injectables Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:OtherSterileInjectablesMember;us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31236473000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3051681000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30186886000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3085476000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30135205000 USD20230808Open filing evidence
2023-01-01 – 2023-03-3149729000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31221633000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3060079000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30171161000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3060767000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30111082000 USD20230808Open filing evidence
2022-01-01 – 2022-03-3150315000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31239732000 USD20240306Open filing evidence
2021-04-01 – 2021-06-3067502000 USD20210806Open filing evidence
2021-01-01 – 2021-06-30122864000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3155362000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31301127000 RestatedUSD20230306Open filing evidence
2020-07-01 – 2020-09-3039092000 USD20201106Open filing evidence
2020-01-01 – 2020-09-30141663000 USD20201106Open filing evidence
2020-04-01 – 2020-06-3071839000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-06-30148813000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-3176974000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31185594000 USD20210226Open filing evidence
2019-07-01 – 2019-09-3043695000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30124026000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3041342000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3080331000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31209729000 USD20210226Open filing evidence

PERCOCET · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:PERCOCETMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31106375000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3026290000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3078791000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3026445000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3052501000 USD20230808Open filing evidence
2023-01-01 – 2023-03-3126056000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31103943000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3025052000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3077483000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3026256000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3052431000 USD20230808Open filing evidence
2022-01-01 – 2022-03-3126175000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31103788000 USD20240306Open filing evidence
2021-07-01 – 2021-09-3026914000 USD20211105Open filing evidence
2021-01-01 – 2021-09-3078695000 USD20211105Open filing evidence
2020-01-01 – 2020-12-31110112000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3027508000 USD20211105Open filing evidence
2020-01-01 – 2020-09-3082789000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3027578000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3055281000 USD20200806Open filing evidence
2019-01-01 – 2019-12-31116012000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3028561000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3088199000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3028878000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3059638000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31122901000 USD20210226Open filing evidence

PERCOCET · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:PERCOCETMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3127703000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31116012000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3028561000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3088199000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3028878000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3059638000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3130760000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31122901000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3030730000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-3093539000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Specialty Products · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:SpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-30150392000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30457926000 USD20231106Open filing evidence
2023-01-01 – 2023-03-31142181000 USD20230508Open filing evidence
2022-07-01 – 2022-09-30146330000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30459251000 USD20231106Open filing evidence
2022-01-01 – 2022-03-31149058000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31633150000 USD20220301Open filing evidence
2021-07-01 – 2021-09-30161917000 USD20211105Open filing evidence
2021-01-01 – 2021-09-30472338000 USD20211105Open filing evidence
2020-01-01 – 2020-12-31497078000 USD20220301Open filing evidence
2020-07-01 – 2020-09-30140120000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30343161000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3068744000 USD20200806Open filing evidence
2020-01-01 – 2020-06-30203041000 USD20200806Open filing evidence
2019-01-01 – 2019-12-31519676000 USD20220301Open filing evidence
2019-07-01 – 2019-09-30131998000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30371057000 USD20201106Open filing evidence
2019-04-01 – 2019-06-30124093000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30239059000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31444575000 USD20210226Open filing evidence

Specialty Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:SpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31134297000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31519676000 USD20200226Open filing evidence
2019-01-01 – 2019-03-31114966000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31444575000 USD20200226Open filing evidence

SUPPRELINLA · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:SUPPRELINLAMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3196849000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3021590000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3073390000 USD20231106Open filing evidence
2023-01-01 – 2023-03-3123577000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31113011000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3031283000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3084852000 USD20231106Open filing evidence
2022-01-01 – 2022-03-3128830000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31114374000 USD20240306Open filing evidence
2021-07-01 – 2021-09-3030069000 USD20211105Open filing evidence
2021-01-01 – 2021-09-3085665000 USD20211105Open filing evidence
2021-01-01 – 2021-03-3128028000 USD20220506Open filing evidence
2020-01-01 – 2020-12-3188182000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3028229000 USD20211105Open filing evidence
2020-01-01 – 2020-09-3063344000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3015395000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3035115000 USD20200806Open filing evidence
2020-01-01 – 2020-03-3119720000 USD20210507Open filing evidence
2019-01-01 – 2019-12-3186797000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3020772000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3066542000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3023714000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3045770000 USD20200806Open filing evidence
2018-01-01 – 2018-12-3181707000 USD20210226Open filing evidence

SUPPRELINLA · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:SUPPRELINLAMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3119720000 USD20200507Open filing evidence
2019-01-01 – 2019-12-3186797000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3020772000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3066542000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3023714000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3045770000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3122056000 USD20200507Open filing evidence
2018-01-01 – 2018-12-3181707000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3020408000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-3060948000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Testopel · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:TestopelMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-318568000 USD20200507Open filing evidence
2019-01-01 – 2019-12-3155244000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3013236000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3040830000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3011780000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3027594000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-315971000 RestatedUSD20200507Open filing evidence
2018-01-01 – 2018-12-3158377000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3015962000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-3044976000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Total Specialty Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:TotalSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2019-07-01 – 2019-09-30131998000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30371057000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-30124093000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30239059000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-31114966000 USD20190509Open filing evidence
2018-01-01 – 2018-12-31502952000 USD20190228Open filing evidence
2018-07-01 – 2018-09-30112236000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30315029000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Vasostrict · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:VasostrictMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31202904000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31531737000 USD20200226Open filing evidence
2019-07-01 – 2019-09-30129691000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30384854000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-30116026000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30255163000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-31139137000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31453767000 USD20200226Open filing evidence
2018-07-01 – 2018-09-30112333000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30332387000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Vasostrict · Sterile Injectables Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:VasostrictMember;us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3193180000 USD20240306Open filing evidence
2022-01-01 – 2022-12-31253696000 USD20240306Open filing evidence
2021-01-01 – 2021-12-31124630000 RestatedUSD20240306Open filing evidence
2021-04-01 – 2021-06-30197121000 USD20210806Open filing evidence
2021-01-01 – 2021-06-30421067000 USD20210806Open filing evidence
2020-01-01 – 2020-12-31785646000 USD20220301Open filing evidence
2020-07-01 – 2020-09-30155412000 USD20201106Open filing evidence
2020-01-01 – 2020-09-30572530000 USD20201106Open filing evidence
2020-04-01 – 2020-06-30214214000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30417118000 USD20210806Open filing evidence
2019-01-01 – 2019-12-31531737000 USD20220301Open filing evidence
2019-07-01 – 2019-09-30129691000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30384854000 USD20201106Open filing evidence
2019-04-01 – 2019-06-30116026000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30255163000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31453767000 USD20210226Open filing evidence

Voltaren Gel · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:VoltarenGelMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-12-3157700000 USD20190228Open filing evidence

Xiaflex · Branded Pharmaceuticals Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:XiaflexMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31475014000 USD20240306Open filing evidence
2023-01-01 – 2023-03-3196910000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31438680000 USD20240306Open filing evidence
2022-01-01 – 2022-03-3199484000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31432344000 USD20240306Open filing evidence
2021-07-01 – 2021-09-30105509000 USD20211105Open filing evidence
2021-01-01 – 2021-09-30312266000 USD20211105Open filing evidence
2021-01-01 – 2021-03-3195270000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31316234000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3088167000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30211022000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3033783000 USD20200806Open filing evidence
2020-01-01 – 2020-06-30122855000 USD20200806Open filing evidence
2020-01-01 – 2020-03-3189072000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31327638000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3082756000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30226118000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3074855000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30143362000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31264638000 USD20210226Open filing evidence

Xiaflex · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=endp:XiaflexMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3189072000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31327638000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3082756000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30226118000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3074855000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30143362000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3168507000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31264638000 USD20200226Open filing evidence
2018-07-01 – 2018-09-3064214000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2018-01-01 – 2018-09-30184855000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence

Adrenalin · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:AdrenalinMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3035460000 USD20181108Open filing evidence
2018-01-01 – 2018-09-30101858000 USD20181108Open filing evidence

Ertapenem For Injection · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:ErtapenemForInjectionMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3025798000 USD20181108Open filing evidence
2018-01-01 – 2018-09-3025798000 USD20181108Open filing evidence

Established Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:EstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3091902000 USD20181108Open filing evidence
2018-01-01 – 2018-09-30272967000 USD20181108Open filing evidence

Opana · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:OpanaMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-300 USD20181108Open filing evidence
2018-01-01 – 2018-09-300 USD20181108Open filing evidence

Other Established Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:OtherEstablishedProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3046115000 USD20181108Open filing evidence
2018-01-01 – 2018-09-30135243000 USD20181108Open filing evidence

Other Specialty Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:OtherSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3043576000 USD20181108Open filing evidence
2018-01-01 – 2018-09-30114202000 USD20181108Open filing evidence

Other Sterile Injectables · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:OtherSterileInjectablesMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3063559000 USD20181108Open filing evidence
2018-01-01 – 2018-09-30210804000 USD20181108Open filing evidence

PERCOCET · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:PERCOCETMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3030730000 USD20181108Open filing evidence
2018-01-01 – 2018-09-3093539000 USD20181108Open filing evidence

SUPPRELINLA · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:SUPPRELINLAMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-3020408000 USD20181108Open filing evidence
2018-01-01 – 2018-09-3060948000 USD20181108Open filing evidence

Total Specialty Products · Branded Specialtyand Established Pharmaceuticals

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:TotalSpecialtyProductsMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2018-07-01 – 2018-09-30128198000 USD20181108Open filing evidence
2018-01-01 – 2018-09-30360005000 USD20181108Open filing evidence

Vasostrict · Branded Sterile Injectables

Product Or Service · Statement Business Segments

Source dimensions us-gaap:ProductOrServiceAxis=endp:VasostrictMember;us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2018-01-01 – 2018-09-30332387000 USD20181108Open filing evidence

Branded Pharmaceuticals Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31859087000 USD20240306Open filing evidence
2023-07-01 – 2023-09-30203368000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30613318000 USD20231106Open filing evidence
2023-04-01 – 2023-06-30212377000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30409950000 USD20230808Open filing evidence
2023-01-01 – 2023-03-31197573000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31851142000 USD20240306Open filing evidence
2022-07-01 – 2022-09-30203501000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30627314000 USD20231106Open filing evidence
2022-04-01 – 2022-06-30218952000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30423813000 USD20230808Open filing evidence
2022-01-01 – 2022-03-31204861000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31893617000 USD20240306Open filing evidence
2021-07-01 – 2021-09-30230977000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30665652000 USD20221109Open filing evidence
2021-04-01 – 2021-06-30228040000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30434675000 USD20220809Open filing evidence
2021-01-01 – 2021-03-31206635000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31781780000 USD20230306Open filing evidence
2020-07-01 – 2020-09-30223682000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30557276000 USD20211105Open filing evidence
2020-04-01 – 2020-06-30129521000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30333594000 USD20210806Open filing evidence
2020-01-01 – 2020-03-31204073000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31855402000 USD20220301Open filing evidence
2019-07-01 – 2019-09-30217313000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30629851000 USD20201106Open filing evidence
2019-04-01 – 2019-06-30209013000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30412538000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31862832000 USD20210226Open filing evidence

Branded Pharmaceuticals Segment · Established Products

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:EstablishedProductsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-12-31229442000 USD20230306Open filing evidence
2022-07-01 – 2022-09-3057171000 USD20221109Open filing evidence
2022-01-01 – 2022-09-30168063000 USD20221109Open filing evidence
2021-01-01 – 2021-12-31260467000 USD20230306Open filing evidence
2021-07-01 – 2021-09-3069060000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30193314000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3060949000 USD20210806Open filing evidence
2021-01-01 – 2021-06-30124254000 USD20210806Open filing evidence
2020-01-01 – 2020-12-31284702000 USD20230306Open filing evidence
2020-07-01 – 2020-09-3083562000 USD20201106Open filing evidence
2020-01-01 – 2020-09-30214115000 USD20201106Open filing evidence
2020-04-01 – 2020-06-3060777000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30130553000 USD20210806Open filing evidence
2019-01-01 – 2019-12-31335726000 USD20210226Open filing evidence
2019-07-01 – 2019-09-3085315000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30258794000 USD20201106Open filing evidence
2018-01-01 – 2018-12-31418257000 USD20210226Open filing evidence

Branded Pharmaceuticals Segment · Lidoderm

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:LidodermMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-03-3110989000 USD20230508Open filing evidence
2022-01-01 – 2022-12-3138727000 USD20230306Open filing evidence
2022-07-01 – 2022-09-309430000 USD20221109Open filing evidence
2022-01-01 – 2022-09-3028331000 USD20221109Open filing evidence
2022-04-01 – 2022-06-3010021000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3018901000 USD20220809Open filing evidence
2022-01-01 – 2022-03-318880000 USD20230508Open filing evidence
2021-01-01 – 2021-12-3143636000 USD20230306Open filing evidence
2021-07-01 – 2021-09-3011686000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3032314000 USD20221109Open filing evidence
2021-04-01 – 2021-06-309439000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3020628000 USD20220809Open filing evidence
2021-01-01 – 2021-03-3111189000 USD20220506Open filing evidence
2020-01-01 – 2020-12-3135234000 USD20230306Open filing evidence
2020-04-01 – 2020-06-30617000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-06-308809000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-318192000 USD20210507Open filing evidence
2019-04-01 – 2019-06-309051000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3017120000 USD20200806Open filing evidence

Branded Pharmaceuticals Segment · Other Established Products

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:OtherEstablishedProductsMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3017076000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3044402000 USD20231106Open filing evidence
2023-04-01 – 2023-06-308979000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3027326000 USD20230808Open filing evidence
2022-01-01 – 2022-12-3186772000 USD20230306Open filing evidence
2022-07-01 – 2022-09-3022689000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3062249000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3018812000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3039560000 USD20230808Open filing evidence
2021-01-01 – 2021-12-31113043000 USD20230306Open filing evidence
2021-07-01 – 2021-09-3030460000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3082305000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3025354000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3051845000 USD20220809Open filing evidence
2020-01-01 – 2020-12-31139356000 USD20230306Open filing evidence
2020-07-01 – 2020-09-3037986000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30104449000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3032582000 USD20210806Open filing evidence
2020-01-01 – 2020-06-3066463000 USD20210806Open filing evidence

Branded Pharmaceuticals Segment · Other Specialty Products

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:OtherSpecialtyProductsMember
PeriodValueUnitFiledEvidence
2023-04-01 – 2023-06-3019839000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3041533000 USD20230808Open filing evidence
2022-01-01 – 2022-12-3170009000 USD20230306Open filing evidence
2022-04-01 – 2022-06-3018246000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3038990000 USD20230808Open filing evidence
2022-01-01 – 2022-03-3120744000 USD20220506Open filing evidence
2021-01-01 – 2021-12-3186432000 USD20230306Open filing evidence
2021-04-01 – 2021-06-3028036000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3048068000 USD20220809Open filing evidence
2021-01-01 – 2021-03-3120032000 USD20220506Open filing evidence
2020-01-01 – 2020-12-3192662000 USD20230306Open filing evidence
2020-04-01 – 2020-06-3019566000 USD20210806Open filing evidence
2020-01-01 – 2020-06-3045071000 USD20210806Open filing evidence
2019-01-01 – 2019-12-31105241000 USD20220301Open filing evidence

Branded Pharmaceuticals Segment · PERCOCET

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:PERCOCETMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-12-31103943000 USD20230306Open filing evidence
2022-07-01 – 2022-09-3025052000 USD20221109Open filing evidence
2022-01-01 – 2022-09-3077483000 USD20221109Open filing evidence
2022-04-01 – 2022-06-3026256000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3052431000 USD20220809Open filing evidence
2022-01-01 – 2022-03-3126175000 USD20220506Open filing evidence
2021-01-01 – 2021-12-31103788000 USD20230306Open filing evidence
2021-07-01 – 2021-09-3026914000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3078695000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3026156000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3051781000 USD20220809Open filing evidence
2021-01-01 – 2021-03-3125625000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31110112000 USD20230306Open filing evidence
2020-04-01 – 2020-06-3027578000 USD20210806Open filing evidence
2020-01-01 – 2020-06-3055281000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3127703000 USD20210507Open filing evidence

Branded Pharmaceuticals Segment · Specialty Products

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:SpecialtyProductsMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31645660000 USD20240306Open filing evidence
2023-04-01 – 2023-06-30165353000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30307534000 USD20230808Open filing evidence
2022-01-01 – 2022-12-31621700000 USD20240306Open filing evidence
2022-07-01 – 2022-09-30146330000 USD20221109Open filing evidence
2022-01-01 – 2022-09-30459251000 USD20221109Open filing evidence
2022-04-01 – 2022-06-30163863000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30312921000 USD20230808Open filing evidence
2022-01-01 – 2022-03-31149058000 USD20220506Open filing evidence
2021-01-01 – 2021-12-31633150000 USD20240306Open filing evidence
2021-07-01 – 2021-09-30161917000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30472338000 USD20221109Open filing evidence
2021-04-01 – 2021-06-30167091000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30310421000 USD20220809Open filing evidence
2021-01-01 – 2021-03-31143330000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31497078000 USD20230306Open filing evidence
2020-04-01 – 2020-06-3068744000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30203041000 USD20210806Open filing evidence
2020-01-01 – 2020-03-31134297000 USD20210507Open filing evidence

Branded Pharmaceuticals Segment · SUPPRELINLA

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:SUPPRELINLAMember
PeriodValueUnitFiledEvidence
2023-04-01 – 2023-06-3028223000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3051800000 USD20230808Open filing evidence
2022-01-01 – 2022-12-31113011000 USD20230306Open filing evidence
2022-07-01 – 2022-09-3031283000 USD20221109Open filing evidence
2022-01-01 – 2022-09-3084852000 USD20221109Open filing evidence
2022-04-01 – 2022-06-3024739000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3053569000 USD20230808Open filing evidence
2021-01-01 – 2021-12-31114374000 USD20230306Open filing evidence
2021-07-01 – 2021-09-3030069000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3085665000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3027568000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3055596000 USD20220809Open filing evidence
2020-01-01 – 2020-12-3188182000 USD20230306Open filing evidence
2020-04-01 – 2020-06-3015395000 USD20210806Open filing evidence
2020-01-01 – 2020-06-3035115000 USD20210806Open filing evidence

Branded Pharmaceuticals Segment · Testopel

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:TestopelMember
PeriodValueUnitFiledEvidence
2020-04-01 – 2020-06-306604000 USD20200806Open filing evidence
2020-01-01 – 2020-06-3015172000 USD20200806Open filing evidence
2019-04-01 – 2019-06-307662000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3013633000 USD20200806Open filing evidence

Branded Pharmaceuticals Segment · Xiaflex

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedPharmaceuticalsSegmentMember;srt:ProductOrServiceAxis=endp:XiaflexMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-30113053000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30327254000 USD20231106Open filing evidence
2023-04-01 – 2023-06-30117291000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30214201000 USD20230808Open filing evidence
2022-01-01 – 2022-12-31438680000 USD20230306Open filing evidence
2022-07-01 – 2022-09-30104014000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30324376000 USD20231106Open filing evidence
2022-04-01 – 2022-06-30120878000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30220362000 USD20230808Open filing evidence
2021-01-01 – 2021-12-31432344000 USD20230306Open filing evidence
2021-07-01 – 2021-09-30105509000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30312266000 USD20221109Open filing evidence
2021-04-01 – 2021-06-30111487000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30206757000 USD20220809Open filing evidence
2020-01-01 – 2020-12-31316234000 USD20230306Open filing evidence
2020-04-01 – 2020-06-3033783000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30122855000 USD20210806Open filing evidence

Branded Specialtyand Established Pharmaceuticals

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31204073000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31855402000 USD20200226Open filing evidence
2019-07-01 – 2019-09-30217313000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30629851000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-30209013000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30412538000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-31203525000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31862832000 USD20200226Open filing evidence

Branded Sterile Injectables

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:BrandedSterileInjectablesMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31336390000 USD20200507Open filing evidence
2019-01-01 – 2019-12-311063131000 USD20200226Open filing evidence
2019-07-01 – 2019-09-30263635000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30777963000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-30244280000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30514328000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-31270048000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31929566000 USD20200226Open filing evidence

Generic Pharmaceuticals

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:GenericPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-31251283000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31879882000 USD20200226Open filing evidence
2019-07-01 – 2019-09-30218012000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-30654322000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-30217784000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-30436310000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-31218526000 USD20200507Open filing evidence
2018-01-01 – 2018-12-311012215000 USD20200226Open filing evidence

Generic Pharmaceuticals Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:GenericPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31650352000 USD20240306Open filing evidence
2023-07-01 – 2023-09-30134382000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30511141000 USD20231106Open filing evidence
2023-04-01 – 2023-06-30178579000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30376759000 USD20230808Open filing evidence
2023-01-01 – 2023-03-31198180000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31795457000 USD20240306Open filing evidence
2022-07-01 – 2022-09-30201435000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30590756000 USD20231106Open filing evidence
2022-04-01 – 2022-06-30203377000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30389321000 USD20230808Open filing evidence
2022-01-01 – 2022-03-31185944000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31740586000 USD20240306Open filing evidence
2021-07-01 – 2021-09-30174306000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30522451000 USD20221109Open filing evidence
2021-04-01 – 2021-06-30167272000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30348145000 USD20220809Open filing evidence
2021-01-01 – 2021-03-31180873000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31783110000 USD20230306Open filing evidence
2020-07-01 – 2020-09-30135508000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30602670000 USD20211105Open filing evidence
2020-04-01 – 2020-06-30215879000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30467162000 USD20210806Open filing evidence
2020-01-01 – 2020-03-31251283000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31879882000 USD20220301Open filing evidence
2019-07-01 – 2019-09-30218012000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30654322000 USD20201106Open filing evidence
2019-04-01 – 2019-06-30217784000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30436310000 USD20200806Open filing evidence
2018-01-01 – 2018-12-311012215000 USD20210226Open filing evidence

International Pharmaceuticals

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:InternationalPharmaceuticalsMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3128659000 USD20200507Open filing evidence
2019-01-01 – 2019-12-31115949000 USD20200226Open filing evidence
2019-07-01 – 2019-09-3030466000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-01-01 – 2019-09-3087428000 USD2019-11-04 · 22:21:50.000ZOpen filing evidence
2019-04-01 – 2019-06-3028650000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-06-3056962000 USD2019-08-05 · 21:00:51.000ZOpen filing evidence
2019-01-01 – 2019-03-3128312000 USD20200507Open filing evidence
2018-01-01 – 2018-12-31142465000 USD20200226Open filing evidence

International Pharmaceuticals Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:InternationalPharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3172516000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3018534000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3055661000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3018868000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3037127000 USD20230808Open filing evidence
2023-01-01 – 2023-03-3118259000 USD20230508Open filing evidence
2022-01-01 – 2022-12-3182643000 USD20240306Open filing evidence
2022-07-01 – 2022-09-3018061000 USD20231106Open filing evidence
2022-01-01 – 2022-09-3063101000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3023614000 USD20230808Open filing evidence
2022-01-01 – 2022-06-3045040000 USD20230808Open filing evidence
2022-01-01 – 2022-03-3121426000 USD20230508Open filing evidence
2021-01-01 – 2021-12-3192906000 USD20240306Open filing evidence
2021-07-01 – 2021-09-3023092000 USD20221109Open filing evidence
2021-01-01 – 2021-09-3068676000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3023918000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3045584000 USD20220809Open filing evidence
2021-01-01 – 2021-03-3121666000 USD20220506Open filing evidence
2020-01-01 – 2020-12-3199337000 USD20230306Open filing evidence
2020-07-01 – 2020-09-3024277000 USD20211105Open filing evidence
2020-01-01 – 2020-09-3075910000 USD20211105Open filing evidence
2020-04-01 – 2020-06-3022974000 USD20210806Open filing evidence
2020-01-01 – 2020-06-3051633000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3128659000 USD20210507Open filing evidence
2019-01-01 – 2019-12-31115949000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3030466000 USD20201106Open filing evidence
2019-01-01 – 2019-09-3087428000 USD20201106Open filing evidence
2019-04-01 – 2019-06-3028650000 USD20200806Open filing evidence
2019-01-01 – 2019-06-3056962000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31142465000 USD20210226Open filing evidence

Sterile Injectables Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31429563000 USD20240306Open filing evidence
2023-07-01 – 2023-09-3095381000 USD20231106Open filing evidence
2023-01-01 – 2023-09-30333664000 USD20231106Open filing evidence
2023-04-01 – 2023-06-30137028000 USD20230808Open filing evidence
2023-01-01 – 2023-06-30238283000 USD20230808Open filing evidence
2023-01-01 – 2023-03-31101255000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31589633000 USD20240306Open filing evidence
2022-07-01 – 2022-09-30118693000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30481892000 USD20231106Open filing evidence
2022-04-01 – 2022-06-30123171000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30363199000 USD20230808Open filing evidence
2022-01-01 – 2022-03-31240028000 USD20230508Open filing evidence
2021-01-01 – 2021-12-311266097000 USD20240306Open filing evidence
2021-07-01 – 2021-09-30343653000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30946998000 USD20221109Open filing evidence
2021-04-01 – 2021-06-30294600000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30603345000 USD20220809Open filing evidence
2021-01-01 – 2021-03-31308745000 USD20220506Open filing evidence
2020-01-01 – 2020-12-311238847000 USD20230306Open filing evidence
2020-07-01 – 2020-09-30251393000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30906997000 USD20211105Open filing evidence
2020-04-01 – 2020-06-30319214000 USD20210806Open filing evidence
2020-01-01 – 2020-06-30655604000 USD20210806Open filing evidence
2020-01-01 – 2020-03-31336390000 USD20210507Open filing evidence
2019-01-01 – 2019-12-311063131000 USD20220301Open filing evidence
2019-07-01 – 2019-09-30263635000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30777963000 USD20201106Open filing evidence
2019-04-01 – 2019-06-30244280000 USD20200806Open filing evidence
2019-01-01 – 2019-06-30514328000 USD20200806Open filing evidence
2018-01-01 – 2018-12-31929566000 USD20210226Open filing evidence

Sterile Injectables Segment · Adrenalin

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember;srt:ProductOrServiceAxis=endp:AdrenalinMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-03-3125575000 USD20230508Open filing evidence
2022-04-01 – 2022-06-3026774000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3060597000 USD20220809Open filing evidence
2022-01-01 – 2022-03-3133823000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31124630000 USD20220301Open filing evidence
2021-07-01 – 2021-09-3028722000 USD20211105Open filing evidence
2021-01-01 – 2021-09-3088136000 USD20211105Open filing evidence
2021-04-01 – 2021-06-3029977000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3059414000 USD20220809Open filing evidence
2020-01-01 – 2020-12-31152074000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3030662000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30120335000 USD20211105Open filing evidence
2019-01-01 – 2019-12-31179295000 USD20220301Open filing evidence
2019-07-01 – 2019-09-3040311000 USD20201106Open filing evidence
2019-01-01 – 2019-09-30133468000 USD20201106Open filing evidence

Sterile Injectables Segment · Other Sterile Injectables

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember;srt:ProductOrServiceAxis=endp:OtherSterileInjectablesMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-3060079000 USD20221109Open filing evidence
2022-01-01 – 2022-09-30171161000 USD20221109Open filing evidence
2022-04-01 – 2022-06-3060767000 USD20220809Open filing evidence
2022-01-01 – 2022-06-30111082000 USD20220809Open filing evidence
2021-01-01 – 2021-12-31239732000 USD20220301Open filing evidence
2021-07-01 – 2021-09-3059234000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30182098000 USD20221109Open filing evidence
2021-04-01 – 2021-06-3067502000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30122864000 USD20220809Open filing evidence
2020-01-01 – 2020-12-31301127000 USD20220301Open filing evidence
2020-07-01 – 2020-09-3065319000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30214132000 USD20211105Open filing evidence
2019-01-01 – 2019-12-31352099000 USD20220301Open filing evidence

Sterile Injectables Segment · Vasostrict

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=endp:SterileInjectablesSegmentMember;srt:ProductOrServiceAxis=endp:VasostrictMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3020827000 USD20231106Open filing evidence
2023-01-01 – 2023-09-3071197000 USD20231106Open filing evidence
2023-04-01 – 2023-06-3024419000 USD20230808Open filing evidence
2023-01-01 – 2023-06-3050370000 USD20230808Open filing evidence
2023-01-01 – 2023-03-3125951000 USD20230508Open filing evidence
2022-01-01 – 2022-12-31253696000 USD20230306Open filing evidence
2022-07-01 – 2022-09-3033697000 USD20231106Open filing evidence
2022-01-01 – 2022-09-30225217000 USD20231106Open filing evidence
2022-04-01 – 2022-06-3035630000 USD20230808Open filing evidence
2022-01-01 – 2022-06-30191520000 USD20230808Open filing evidence
2022-01-01 – 2022-03-31155890000 USD20230508Open filing evidence
2021-01-01 – 2021-12-31901735000 USD20230306Open filing evidence
2021-07-01 – 2021-09-30255697000 USD20221109Open filing evidence
2021-01-01 – 2021-09-30676764000 USD20221109Open filing evidence
2021-04-01 – 2021-06-30197121000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30421067000 USD20220809Open filing evidence
2021-01-01 – 2021-03-31223946000 USD20220506Open filing evidence
2020-01-01 – 2020-12-31785646000 USD20230306Open filing evidence
2020-07-01 – 2020-09-30155412000 USD20211105Open filing evidence
2020-01-01 – 2020-09-30572530000 USD20211105Open filing evidence
2020-01-01 – 2020-03-31202904000 USD20210507Open filing evidence